Zhejiang CONBA Pharmaceutical Co., Ltd.SSE: 600572

Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its Subsidiary

· Issued by Zhejiang CONBA Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Zhejiang CONBA Pharmaceutical Co., Ltd. announced that its subsidiary has received a drug registration certificate for Blonanserin Tablets from the National Medical Products Administration. The drug is classified as a second-generation antipsychotic used for treating schizophrenia and has been approved for sale in China. The company plans to actively arrange for the production and market launch of this drug, which is expected to positively impact its performance. Investors are cautioned about potential uncertainties in future sales and revenue due to market and policy factors.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Zhejiang CONBA Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhejiang CONBA Pharmaceutical

Later from Zhejiang CONBA Pharmaceutical

All Zhejiang CONBA Pharmaceutical news releases